ATE420656T1 - Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese - Google Patents

Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese

Info

Publication number
ATE420656T1
ATE420656T1 AT01932977T AT01932977T ATE420656T1 AT E420656 T1 ATE420656 T1 AT E420656T1 AT 01932977 T AT01932977 T AT 01932977T AT 01932977 T AT01932977 T AT 01932977T AT E420656 T1 ATE420656 T1 AT E420656T1
Authority
AT
Austria
Prior art keywords
regeneration
arginase
methods
nervous system
compositions
Prior art date
Application number
AT01932977T
Other languages
English (en)
Inventor
Marie T Filbin
Rajiv R Ratan
Original Assignee
Univ City
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ City, Beth Israel Hospital filed Critical Univ City
Application granted granted Critical
Publication of ATE420656T1 publication Critical patent/ATE420656T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
AT01932977T 2000-05-05 2001-05-04 Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese ATE420656T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20230700P 2000-05-05 2000-05-05

Publications (1)

Publication Number Publication Date
ATE420656T1 true ATE420656T1 (de) 2009-01-15

Family

ID=22749330

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01932977T ATE420656T1 (de) 2000-05-05 2001-05-04 Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese

Country Status (9)

Country Link
US (2) US7741310B2 (de)
EP (1) EP1278537B1 (de)
AT (1) ATE420656T1 (de)
AU (2) AU2001259453B2 (de)
CA (1) CA2408255A1 (de)
DE (1) DE60137414D1 (de)
ES (1) ES2322332T3 (de)
HK (1) HK1054680A1 (de)
WO (1) WO2001085981A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002343609B2 (en) 2001-11-16 2008-12-11 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
EP1448183A2 (de) * 2001-11-16 2004-08-25 ALS Therapy Development Foundation, Inc. Behandlung von neurodegenerativen erkrankungen durch modulieren des polyaminenbiosynthesewegs
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
SI1583541T1 (sl) * 2002-11-20 2011-08-31 Neuronova Ab Spojine in postopki za povečanje nevrogeneze
CA2586048C (en) 2004-10-29 2014-03-11 Gregg A. Howe Protection against herbivores
EP1904092A4 (de) * 2005-07-21 2011-08-17 Buck Inst For Age Res Fibroblasten-wachstumsfaktor-2 fördert neurogenese und nervenschutz und verlängert die lebensdauer bei der huntington-krankheit
US8367615B2 (en) 2006-03-30 2013-02-05 Research Foundation Of City University Of New York Stimulation of neuron regeneration by secretory leukocyte protease inhibitor
WO2008086573A1 (en) * 2007-01-19 2008-07-24 Howard Florey Institute Of Experimental Physiology And Medicine Use of galanin in a method of treating neurodegenerative diseases or conditions
WO2009020601A2 (en) * 2007-08-03 2009-02-12 Cornell University Atf4 inhibitors and their use for neural protection, repair, regeneration, and plasticity
US20110016548A1 (en) * 2009-07-16 2011-01-20 University Of Southern California Control of endogenous dnmt1 gene expression by exogenous binary regulatory systems
US11268655B2 (en) 2018-01-09 2022-03-08 Cryoport, Inc. Cryosphere
US20210340516A1 (en) * 2020-04-29 2021-11-04 Augusta University Research Institute, Inc. Compositions containing arginase 1 for the treatment of neurovascular and retinal vascular disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395612A (en) * 1990-03-27 1995-03-07 Cornell Research Foundation, Inc. Method for treating systemic hypotension caused by sepsis or cytokine using arginase in combination with an α1 adrenergic agonist
AU2300092A (en) * 1991-07-03 1993-02-11 Nathan E. Scott Prostaglandin e2 treatment of impotence
HUT70275A (en) 1991-07-10 1995-09-28 Regeneron Pharma Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules
FR2717496B1 (fr) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US6096716A (en) * 1994-12-12 2000-08-01 The Board Of Regents, The University Of Texas System Liposome-mediated transfection of central nervous system cells
AU731044B2 (en) * 1995-06-27 2001-03-22 Research Foundation Of Cuny, Hunter College Compositions and methods using myelin-associated glycoprotein (MAG) and inhibitors thereof
US5731284A (en) 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
AU2251897A (en) * 1996-02-13 1997-09-02 Trustees Of The University Of Pennsylvania, The Method of treating liver disorders
US6222022B1 (en) 1996-03-14 2001-04-24 Washington University Persephin and related growth factors
US5741778A (en) 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US5990168A (en) 1996-04-18 1999-11-23 Alberta Cancer Board Methods and compositions for the treatment of ataxia telangiectasia
WO1997039629A1 (en) 1996-04-25 1997-10-30 Genetic Therapy, Inc. Viral vectors including polynucleotides encoding neurotrophic factors and uses therefor
AU9797998A (en) * 1997-10-10 1999-05-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for inhibiting arginase activity
WO1999043345A1 (en) 1998-02-26 1999-09-02 Eisai Co., Ltd. Amino acid degrading enzymes modulate cell death
US6284540B1 (en) * 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
US6708712B2 (en) 2001-10-04 2004-03-23 Illinois Tool Works Inc. Pressure regulator utilizing a disc spring
AU2002343609B2 (en) * 2001-11-16 2008-12-11 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
CA2477400A1 (en) * 2002-03-01 2003-09-12 Marc Rothenberg Treatment for asthma or allergies

Also Published As

Publication number Publication date
WO2001085981A3 (en) 2002-03-14
EP1278537A2 (de) 2003-01-29
DE60137414D1 (de) 2009-03-05
US8673594B2 (en) 2014-03-18
WO2001085981A2 (en) 2001-11-15
US20100216710A1 (en) 2010-08-26
CA2408255A1 (en) 2001-11-15
US20030215428A1 (en) 2003-11-20
HK1054680A1 (zh) 2003-12-12
US7741310B2 (en) 2010-06-22
AU2001259453B2 (en) 2006-08-31
AU5945301A (en) 2001-11-20
ES2322332T3 (es) 2009-06-19
EP1278537B1 (de) 2009-01-14

Similar Documents

Publication Publication Date Title
DE69633336D1 (de) Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält
WO2002045749A3 (en) Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
ATE420656T1 (de) Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese
ATE323482T1 (de) Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten
ATE533484T1 (de) Verwendung von rotigotin zur behandlung oder zur prävention des dopaminergen neuronenverlustes
DE69942702D1 (de) Zusammenstellungen und methoden zur behandlung der alzheimerschen krankheit, schäden des zentralnervensystems und entzündlichen erkrankungen
DE60335244D1 (de) Behandlung von verletzungen des zentralen nervensystems
ATE425750T1 (de) Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung
WO2002036829A3 (en) Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries
WO2004096245A3 (en) Muscle derived cells (mdcs) for promoting and enhancing nerve repair and regeneration
PA8468501A1 (es) Compuestos heterociclicos como inhibidores de enzimas rotamasas
ATE254172T1 (de) Verbeugende oder therapeutische mittel für die alzheimer-krankheit, eine siebtest-methode, und die menschliche tau-protein-kinase
ATE504310T1 (de) Neuroprotektive, antithrombotische und anti- entzündliche anwendungen von aktiviertem protein c
ATE375141T1 (de) Verfahren und mittel zur behandlung und vorbeugung von erkrankungen der hinteren augenkammer
WO2004026107A3 (en) Kits and methods for assessing skin health
DK1373502T3 (da) Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf
WO2005061002A3 (en) Composition and methods for modulating cns activity
DE602004022284D1 (de) Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid-neurotoxizität und mikrogliosis
PT1255734E (pt) Derivados de isatina com actividade neurotrofica
DE69620027D1 (de) Verwendung von eliprodil zur herstellung eines arzneimittels zur behandlung von ischämischen störungen der retina oder des sehnervs
DE60326742D1 (de) Piperazin und piperadin-derivate für die behandlung von neurologischen krankheiten
WO2004016751A3 (en) Methods of treating neurodegenerative diseases
GEP20063859B (en) Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
WO2003030836A3 (en) Neuronal regeneration
EP1469730A4 (de) Verfahren und zusammensetzungen zur behandlung der parkinson-krankheit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties